Abstract
Background: Phosphodiesterase-5 (PDE5) inhibitors demonstrate off-label anticancer properties, acting through a variety of mechanisms that ultimately reduce tumor proliferation.
Method: Combining PDE5 inhibitors with other anti-oncotic agents further enhances their effectiveness against tumors. Mechanistically, PDE5 inhibitors have been shown to inhibit ATP binding cassette (ABC) transporter protein activity, potentiate reactive oxygen species (ROS) activity, decrease FADD-like IL-1β-converting enzyme (FLICE)- inhibitory protein (c-FLIP) expression, increase blood-brain tumor barrier (BTB) permeability, and, when administered as a combination therapy, sensitize tumors to platinum.
Conclusion: This review offers insights into the various mechanisms by which PDE5 inhibitors exert their antineoplastic actions.
Keywords: ABC transporter, anticancer therapy, antineoplastic agents, phosphodiesterase inhibitors, reactive oxygen species, sildenafil, Viagra®.
Current Cancer Therapy Reviews
Title:PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy
Volume: 13 Issue: 2
Author(s): Robert W. Lyday , Abigail M. Etters, Chris Kim, Fernando Magana, Gabriel M. Pontipiedra, Naveen K.M. Singh and Samuel Kadavakollu *
Affiliation:
- Department of Biomedical Sciences, Burrell College of Osteopathic Medicine, Las Cruces, NM 88001,United States
Keywords: ABC transporter, anticancer therapy, antineoplastic agents, phosphodiesterase inhibitors, reactive oxygen species, sildenafil, Viagra®.
Abstract: Background: Phosphodiesterase-5 (PDE5) inhibitors demonstrate off-label anticancer properties, acting through a variety of mechanisms that ultimately reduce tumor proliferation.
Method: Combining PDE5 inhibitors with other anti-oncotic agents further enhances their effectiveness against tumors. Mechanistically, PDE5 inhibitors have been shown to inhibit ATP binding cassette (ABC) transporter protein activity, potentiate reactive oxygen species (ROS) activity, decrease FADD-like IL-1β-converting enzyme (FLICE)- inhibitory protein (c-FLIP) expression, increase blood-brain tumor barrier (BTB) permeability, and, when administered as a combination therapy, sensitize tumors to platinum.
Conclusion: This review offers insights into the various mechanisms by which PDE5 inhibitors exert their antineoplastic actions.
Export Options
About this article
Cite this article as:
Lyday W. Robert , Etters M. Abigail , Kim Chris , Magana Fernando, Pontipiedra M. Gabriel , Singh K.M. Naveen and Kadavakollu Samuel *, PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy, Current Cancer Therapy Reviews 2017; 13 (2) . https://dx.doi.org/10.2174/1573394713666170731152749
DOI https://dx.doi.org/10.2174/1573394713666170731152749 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase IIα (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in Cancer
Current Cancer Drug Targets Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry PDZ Structure and Implication in Selective Drug Design against Cystic Fibrosis
Current Drug Targets DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design Synthesis, Biochemical Evaluation and Rationalisation of a Series of (3-O-Sulfonate) Derivatives of Estrone (E1) as Probes of the Active Site of Type 3 of the 17β-Hydroxysteroid Dehydrogenase (17β-HSD) Family of Enzymes
Letters in Drug Design & Discovery The Dynamics of the Hypothalamic-Pituitary-Ovarian Axis, ReproductivePerformance and Sexuality Following Bariatric Surgery
Current Women`s Health Reviews Genome-Wide Integrated Analyses of Androgen Receptor Signaling in Prostate Cancer Based on High-Throughput Technology
Current Drug Targets DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
Current Medicinal Chemistry Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets “Unlocking” the Blood-Testis Barrier and the Ectoplasmic Specialization by Cytokines During Spermatogenesis: Emerging Targets for Male Contraception
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Immunological Aspects of the Prostate Gland and Related Diseases
Current Immunology Reviews (Discontinued) Engineered Biosynthesis of Medicinally Important Plant Natural Products in Microorganisms
Current Topics in Medicinal Chemistry Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science Gene Electrotransfer: A Mechanistic Perspective
Current Gene Therapy New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Current Drug Targets The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Nano-zinc Coordination with the Ligands of Carboplatin, Oxaliplatin and Nedaplatin. Synthesis, Characterization and Biological Properties
Letters in Organic Chemistry Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Current Drug Targets